Frontotemporal dementia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Frontotemporal dementia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Accuracy of Tau PET ([18F]RO6958948) and Vizamyl (Flutemetamol 18F) in Diagnosing Mild Cognitive Symptoms and Risk of Alzheimer’s Disease https://clinicaltrials.eu/trial/study-on-the-accuracy-of-tau-pet-18fro6958948-and-vizamyl-flutemetamol-18f-in-diagnosing-mild-cognitive-symptoms-and-risk-of-alzheimers-disease/ Wed, 29 Apr 2026 15:05:45 +0000 https://clinicaltrials.eu/trial/study-on-the-accuracy-of-tau-pet-18fro6958948-and-vizamyl-flutemetamol-18f-in-diagnosing-mild-cognitive-symptoms-and-risk-of-alzheimers-disease/ The study focuses on understanding and improving the diagnosis of certain brain disorders known as neurodegenerative disorders. These include conditions like Alzheimer’s disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration, and mild cognitive impairment. The study uses two special substances, Vizamyl and [18F]RO6958948, which are injected into the body to help doctors see changes in the brain using a type of scan called PET (Positron Emission Tomography).

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

]]> Study on the Safety and Effects of DNL593 for Patients with Frontotemporal Dementia https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-dnl593-for-patients-with-frontotemporal-dementia/ Wed, 29 Apr 2026 15:05:44 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-dnl593-for-patients-with-frontotemporal-dementia/ This clinical trial is focused on studying a condition known as Frontotemporal Dementia (FTD), which is a type of dementia that affects the frontal and temporal lobes of the brain, leading to changes in personality, behavior, and language. The study will evaluate a treatment called DNL593, which is a solution for injection developed by Denali Therapeutics Inc. The trial will also involve a placebo, which is a substance with no active medication, to compare the effects of the treatment.

The purpose of the study is to assess the safety and tolerability of DNL593 in both healthy participants and those with Frontotemporal Dementia. The study is divided into several parts. Initially, healthy participants will receive a single dose of the treatment to evaluate its safety. Following this, participants with Frontotemporal Dementia will receive multiple doses over a period of up to 18 months. This will help researchers understand how the treatment works in the body and its potential effects on the disease.

Throughout the study, participants will be monitored for any side effects or changes in their health. This includes regular checks of vital signs, laboratory tests, and physical examinations. The study aims to gather important information about how DNL593 is processed in the body and its impact on the disease, which could lead to new insights and potential treatments for Frontotemporal Dementia.

]]> Study on the Safety and Effects of LY3884963 for Patients with Fronto-Temporal Dementia with Progranulin Mutations https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ly3884963-for-patients-with-fronto-temporal-dementia-with-progranulin-mutations/ Wed, 29 Apr 2026 15:01:02 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ly3884963-for-patients-with-fronto-temporal-dementia-with-progranulin-mutations/ This clinical trial is focused on studying a condition known as Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN). This is a type of dementia that affects the brain, leading to changes in behavior, language, and movement. The study is testing a new treatment called LY3884963, which is an investigational gene therapy. This therapy uses a special viral vector to deliver a gene into the patient’s cells, aiming to increase levels of a protein called progranulin, which is important for brain health.

The purpose of the study is to evaluate the safety and effects of different doses of LY3884963 on progranulin levels in patients with FTD-GRN. Participants will receive the treatment through an injection into a specific area at the base of the skull. The study will monitor the participants over time to see how their progranulin levels change in their blood and cerebrospinal fluid, which is the fluid surrounding the brain and spine. Some participants may also receive other medications like Sirolimus or Rituximab to help manage their condition.

Throughout the study, researchers will keep track of any side effects or changes in the participants’ health. They will also use imaging techniques like MRI to check for any changes in the brain and spine. The study aims to provide valuable information on how safe and effective LY3884963 is for treating FTD-GRN, potentially leading to new treatment options for this challenging condition.

]]> Study on AVB-101 for Patients with Frontotemporal Dementia with Progranulin Mutations https://clinicaltrials.eu/trial/study-on-avb-101-for-patients-with-frontotemporal-dementia-with-progranulin-mutations/ Wed, 29 Apr 2026 14:30:02 +0000 https://clinicaltrials.eu/trial/study-on-avb-101-for-patients-with-frontotemporal-dementia-with-progranulin-mutations/ This clinical trial is focused on studying a condition known as Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). This is a type of dementia that affects the frontal and temporal lobes of the brain, often leading to changes in personality, behavior, and language. The treatment being tested in this study is called AVB-101, which is a solution designed for injection or infusion. AVB-101 is a special type of therapy that uses a Recombinant AAV-9 vector to deliver the human progranulin protein directly into the brain. This is done through a procedure called intrathalamic infusion, which involves administering the treatment into a specific area of the brain known as the thalamus.

The purpose of this study is to evaluate the safety and initial effectiveness of AVB-101 in individuals with FTD-GRN. Participants in the study will receive a one-time administration of AVB-101, and their health will be monitored over a period of time to observe any changes or side effects. The study will take place over several years, with an initial follow-up period of 26 weeks and a total follow-up period of up to five years. During this time, researchers will keep track of any adverse events, changes in vital signs, and other health indicators to ensure the treatment is safe and to gather preliminary data on its potential benefits.

Throughout the study, participants will undergo various assessments, including MRI scans and laboratory tests, to monitor their condition and the effects of the treatment. The study aims to provide valuable information on the safety and potential benefits of AVB-101 for people with FTD-GRN, contributing to the development of new treatment options for this challenging condition.

]]> Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations https://clinicaltrials.eu/trial/study-on-the-effects-of-latozinemab-for-patients-with-frontotemporal-dementia-due-to-progranulin-gene-mutations/ Wed, 29 Apr 2026 14:22:57 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-latozinemab-for-patients-with-frontotemporal-dementia-due-to-progranulin-gene-mutations/ This clinical trial is focused on studying Frontotemporal Dementia (FTD), a condition that affects the brain and can lead to changes in behavior and personality, as well as difficulties with language and movement. The study is testing a treatment called latozinemab, also known by its code name AL001. This treatment is given as a solution through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate how effective and safe AL001 is for individuals who are at risk for or have FTD due to specific genetic changes, known as heterozygous mutations in the progranulin gene.

Participants in the study will be randomly assigned to receive either the AL001 treatment or a placebo, which is a sterile solution that looks like the treatment but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations or bias. The study will take place over a period of time, with participants receiving the treatment or placebo and undergoing regular assessments to monitor their condition and any changes that occur.

The trial aims to measure changes in participants’ symptoms and overall condition at various points during the study, specifically at weeks 48, 72, and 96. These assessments will help determine the effectiveness of AL001 in managing the symptoms of FTD and its impact on participants’ quality of life. The study will also monitor the safety of the treatment to ensure that it does not cause any harmful side effects. By participating in this trial, researchers hope to gather valuable information that could lead to better treatment options for individuals affected by Frontotemporal Dementia.

]]>